%0 Journal Article %A Quiroga, Borja %A Soler, Maria Jose %A Ortiz, Alberto %A Orero, Esther %A Tejedor, Sandra %A Jarava-Mantecon, Carlos Jesus %A Gomez-Perez, Virginia Olinda %A Marin-Franco, Antonio Jose %A Alfaro-Sanchez, Christian %A Puerta-Carretero, Marta %A Jaldo-Rodriguez, Maria Teresa %A Carnerero-Di-Riso, Manuel Antonio %A Martinez, Shaira %A Caldeon-Gonzalez, Carmen %A Cervienka, Michal %A Macias-Carmona, Nicolas %A Arroyo, David %A Perez-Del-Valle, Katia M %A de-Arriba, Gabriel %A Mazuecos, Auxiliadora %A Cazorla, Juan Manuel %A Pereira, Monica %A Gonzalez-Parra, Emilio %A Sanchez-Marquez, Maria Gabriela %A Lancho-Novillo, Carolina %A Toyos-Ruiz, Carmen %A Aguilar-Cervera, Maria Cinta %A Muñoz-Ramos, Patricia %A Sanchez-Horrillo, Ana %A Jimeno-Martin, Isabel %A Toapanta, Nestor %A Cigarran-Guldris, Secundino %A Folgueiras-Lopez, Montserrat %A Valero-San-Cecilio, Rosalia %A Villacorta-Linaza, Blanca %A Minguela-Pesquera, Ignacio %A Santana-Estupiñan, Raquel %A Zamora, Rocio %A Soriano, Sagrario %A Muñoz-de-Bustillo, Eduardo %A Pizarro-Sanchez, Maria Soledad %A Martinez-Puerto, Ana Isabel %A Yugueros, Alejandra %A Muñiz-Pacios, Laura %A Leyva, Alba %A Rojas, Jose %A Gansevoort, Ron T %A de-Sequera, Patricia %T Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. %D 2022 %U http://hdl.handle.net/10668/20489 %X Information on the effect of a third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in advanced CKD is incomplete (1). We assessed the humoral response up to 6 months after receipt of two or three doses of the SARS-CoV-2 vaccine across the CKD spectrum. SENOVAC is a prospective, multicentric study of cohorts of patients with CKD: kidney transplant, hemodialysis (HD), peritoneal dialysis (PD), and nondialysis CKD (eGFR <30 ml/min per 1.73 m2) (2,3). Patients were vaccinated against SARS-CoV-2 during routine clinical care. Some patients received a third dose of an mRNA vaccine. This depended on the timing of vaccination drives by local health authorities. We assessed anti-Spike antibodies (CLIA, Covid-19 Spike Quantitative Virla IgG Monotest; Vircell SL, Spain) kinetics at a prespecified 6-month time point after completing the original vaccination schedule (2,3). The study was approved by the ethics committee of Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (ISFJD) (February 2021). %K COVID-19 %K SARS-CoV-2 %K Anti-Spike %K Chronic kidney disease %K Hemodialysis %K Kidney transplantation %K Peritoneal dialysis %K Vaccination %~